Medications for Type 2 Diabetes and Chronic Kidney Disease

A Guide to Medications for Type 2 Diabetes and Chronic Kidney Disease

A Guide to Medications for Type 2 Diabetes and Chronic Kidney Disease
Jose A. Bernat Bacete/Getty Images
Diabetes is the most common cause of chronic kidney disease (CKD). Around 33 percent of adults with diabetes also have CKD.

When diabetes causes CKD, it’s sometimes called diabetic kidney disease.
Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your kidneys could become less effective at filtering your blood and regulating your bodily fluids over time. The most severe cases of kidney disease eventually require either a kidney transplant or dialysis treatment.

In its earlier stages, diabetic kidney disease can be prevented or treated with lifestyle changes and by keeping your metabolic health under control. That includes hitting your blood sugar targets, and taking prescription medications for diabetes and common conditions such as high blood pressure and high cholesterol.

A variety of other medications are approved specifically to treat kidney disease in people with type 2 diabetes, helping to improve outcomes for people with both conditions.

Diabetes Drugs That Directly Benefit the Kidneys

The U.S. Food and Drug Administration (FDA) has approved two drug classes for managing type 2 diabetes that have direct and significant benefits on kidney health: sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.

SGLT2 Inhibitors

SGLT2 inhibitors are daily pills that block your body’s ability to reabsorb sugar (glucose) from your blood, causing extra sugar to leave your body through urine.

These drugs were originally intended to help lower blood-sugar levels in people with type 2 diabetes. But long-term studies have also found that SGLT2 inhibitors offer significant kidney and heart health protection. Some of these studies were stopped early, because the evidence in favor of kidney benefits was so overwhelming that it became unethical to keep giving a placebo (a sham treatment) to volunteers with diabetes and CKD in the control group.

These trials have found that SGLT2 inhibitors can slow kidney-function decline by up to 60 percent, which significantly delays the development of severe outcomes like kidney failure and early death.

SGLT2 inhibitors can be prescribed to people at most stages of CKD, including those with advanced kidney failure or a high risk of kidney failure: “People with advanced CKD but who are not yet on dialysis can also benefit,” says Alexander Turchin, MD, director of quality in diabetes at Brigham and Women’s Hospital, and an associate professor at Harvard Medical School in Boston, Massachusetts.

It’s less clear whether or not SGLT2 inhibitors protect the kidney health of people who haven’t yet developed measurable kidney disease, as this hasn’t yet been tested rigorously. “But, based on what we know so far, it might be reasonably expected that there would be benefits to kidney health from their use,” says Dr. Turchin.

SGLT2 inhibitors on the market that are approved for the treatment or prevention of kidney disease include:

  • canagliflozin (Invokana)
  • dapagliflozin (Farxiga)
  • empagliflozin (Jardiance)
Common side effects include:

  • Dehydration
  • Urinating more often
  • Yeast infections and urinary tract infections (UTIs)
  • Low blood pressure
  • Low blood sugar
Along with their kidney benefits, SGLT2 inhibitors can help protect your heart and blood vessels by reducing blood pressure. That may reduce the risk of major heart events and hospitalizations for heart failure. SGLT2 inhibitors are generally safe for people with kidney issues, in whom many medications cause adverse effects.

GLP-1 Receptor Agonists

GLP-1 receptor agonists are best known as blockbuster diabetes and obesity medications. They mimic a hormone that triggers the release of insulin from your pancreas to support digestion and slow down your liver’s release of glucose to control blood sugar. They also increase how full you feel after meals and slow digestion.

GLP-1s can improve kidney health by keeping blood sugar levels within your target range and provoking weight loss. It’s also possible that they reduce inflammation in your kidneys or remove excess sodium from your body, but more research is needed to confirm the direct effects.

Though there are several GLP-1 drugs on the market, only one has been approved for the treatment of kidney disease in people with type 2 diabetes: semaglutide (Ozempic).

In a major trial, semaglutide significantly slowed the rate of kidney-function decline, reduced the risk of major kidney or cardiovascular events by 24 percent, and reduced the risk of death by 20 percent.

Early evidence suggests that tirzepatide (Mounjaro) also protects kidney function, but researchers have not yet completed the long and rigorous trials necessary to fully test the drug’s effect on kidney disease.

Though the evidence for kidney protection may be stronger for SGLT2 inhibitors than it is for GLP-1s, it’s not truly known if one drug is more effective than the other: “No one has compared them directly to each other, but SGLT2 inhibitors seem to be more effective in preventing [the] progression of kidney disease than GLP1s,” says Turchin.

And it’s possible to take them both at the same time, he says. “I wouldn’t usually think of it as a choice between the two. For all we know, combining both classes of medications may result in a greater benefit — although, again, testing hasn’t yet examined this. I usually recommend that my patients with kidney disease take both to prevent disease progression as much as possible.”

Semaglutide (Ozempic), the long-acting GLP-1 with FDA approval to treat type 2 diabetes and CKD, is available as a weekly injection. The most common side effects are gastrointestinal symptoms, including nausea, vomiting, and diarrhea. If you’re already using glucose-lowering medications such as insulin, you may need to change your dosage when starting semaglutide.

Other Drugs Approved for Diabetic Kidney Disease

Several other drugs are approved to help treat kidney disease in people who also have type 2 diabetes.

ACE Inhibitors and ARBs

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are blood pressure medications that doctors often recommend for people with CKD. These drugs reduce your body’s amount of (or response to) a hormone that constricts blood vessels within your kidneys. Reducing this hormone’s effect lowers blood pressure in the kidneys and directly benefits kidney health in people with CKD.

ACE inhibitors and ARBs are often the first medications a doctor will prescribe to try to slow the progression of CKD with diabetes. Some doctors may even prescribe them before signs of kidney disease develop, and they can be used by people who don’t have high blood pressure.

Side effects may include:

  • Angioedema, a rare but serious side effect that can cause swelling of your mouth, tongue, and throat
  • Dry cough (specific to ACE inhibitors)
  • High potassium levels
  • Low blood pressure
  • Slight decrease in eGFR when your kidneys rest a little

Finerenone (Kerendia)

Finerenone is a class of drug known as a selective mineraloid receptor that has FDA approval as a tablet for people with CKD and type 2 diabetes.

This medication can help reduce scarring on the kidneys, decreasing the risk of kidney failure. It can also lower the risk of a heart attack, hospitalization due to heart failure, and death from heart disease.

Finerenone isn’t recommended for people with advanced kidney disease.

Side effects may include high potassium, low blood pressure, and low sodium.

Turchin says other, more-affordable medications from the same medication class — such as eplerenone and spironolactone — don’t carry FDA approval for treating kidney scarring but generally work very similarly. “A doctor could conceivably prescribe these off-label for patients who cannot afford finerenone,” he says.

Drugs to Manage Diabetic Kidney Disease Symptoms

Diabetic kidney disease is linked with a variety of related conditions, complications, signs, and symptoms. As such, a healthcare professional may need to prescribe a range of medications to treat these symptoms as they occur:

  • Anemia A low red blood–cell count is common in people with CKD. A doctor may prescribe several medications to manage CKD-related anemia. These include erythropoiesis-stimulating agents (ESAs) to stimulate your body to make more red blood cells, iron supplements to provide iron for red blood cell production, and hypoxia-inducible factor (HIF) stabilizers to boost red blood–cell production.
  • High Phosphorus People with advanced CKD may develop a phosphorus buildup, as the kidneys can no longer filter the mineral well, causing an imbalance. Medications like phosphate binders can help reduce phosphorus levels, while calcimimetics, calcium supplements, and vitamin D supplements can help balance mineral levels.
  • High Potassium Diabetic kidney disease can also increase potassium levels too much, which may lead to heart rhythm problems called arrhythmias. A doctor may prescribe potassium binders to help eliminate potassium when the kidneys struggle to do so to help prevent arrhythmias.
  • Metabolic Acidosis A doctor may prescribe sodium bicarbonate to reduce the acidity of your blood.

Drugs for Metabolic Health and Related Conditions

Treating kidney disease relies heavily on managing your overall metabolic health. Managing your diabetes, and related conditions like high blood pressure (hypertension) and high cholesterol, will have significant benefits for your kidneys.

Diet, exercise, and other lifestyle choices are key for the treatment of CKD, but your doctor may also prescribe other drugs to help with these risk factors.

Metformin, the first-line medication for type 2 diabetes, may have direct benefits for kidney health. The drug may directly reduce diabetic kidney disease by helping control inflammation in your kidneys, cell damage, and scarring.

Hypertension can increase pressure inside your kidneys, causing a cycle of worsening kidney damage and climbing blood pressure.

“High blood pressure is a major risk factor for the development and progression of kidney disease,” says Turchin. “Healthcare professionals recommend that patients who have kidney disease or are at high risk of developing kidney disease — such as those with heart disease, heart failure, or diabetes, and people older than 65 years of age with hypertension — receive treatment to achieve a blood pressure of less than 130/80 mm Hg.”

Doctors have many options to treat blood pressure in addition to ACE inhibitors and ARBs, including:

  • Beta-Blockers These medications block a hormone called adrenaline, which helps to slow and soften the heartbeat.
  • Diuretics Also known as water pills, these drugs help you pass more urine, letting your kidneys pass more sodium and water.
  • Calcium Channel Blockers These medications reduce blood pressure by relaxing the blood vessels and blocking calcium from entering heart and blood vessel cells.
A class of medications called statins can treat high cholesterol in people with CKD and type 2 diabetes.

These medications work by reducing how much cholesterol your liver makes and improving how much it can remove from your blood. Statins are useful for reducing heart disease risk as part of a lifestyle that includes a healthy diet.

High cholesterol can also worsen CKD and lead to kidney failure.

However, Turchin says that the role of high cholesterol in CKD development is less clear than other associated conditions. “Currently, patients with kidney disease should be treated for high cholesterol the same way as everyone else,” he says. “Cholesterol management may be helpful if their ‘bad’ LDL cholesterol is very high, if they already have heart disease, stroke, or diabetes, or if they have multiple other risk factors for heart disease or stroke.”

The Takeaway

  • Diabetes is the leading cause of chronic kidney disease (CKD), and managing blood sugar levels is key to preventing or slowing the progression of kidney damage.
  • SGLT2 inhibitors and GLP-1 receptor agonists are approved by the FDA to help manage both type 2 diabetes and CKD. These medications have been shown in trials to slow the decline of kidney function.
  • Other medications approved to treat diabetic kidney disease may include ACE inhibitors and ARBs to control blood pressure, and finerenone to reduce kidney scarring.
  • If you have diabetic kidney disease, it’s extremely important to manage your overall metabolic health by making the right diet, exercise, and medication choices. Managing related health issues, like high blood pressure, is crucial for overall kidney health.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Kidney Disease: Fact Sheet. National Kidney Foundation. August 8, 2024.
  2. Diabetes and Kidney Disease (Stages 1-4). National Kidney Foundation. 2025.
  3. Thomas MC et al. SGLT2 Inhibitors for Patients With Type 2 Diabetes and CKD: A Narrative Review. Endocrine Connections. July 31, 2023.
  4. Dapagliflozin (Oral Route). Mayo Clinic. October 1, 2025.
  5. GLP-1 Receptor Agonists (GLP-1 RAs). National Kidney Foundation. September 16, 2024.
  6. FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression. JAMA. February 28, 2025.
  7. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes. The New England Journal of Medicine. July 11, 2024.
  8. Apperloo EM et al. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials. Diabetes Care. January 2, 2025.
  9. Diabetic Nephropathy (Kidney Disease). Mayo Clinic. October 24, 2023.
  10. ACE Inhibitors and ARBs. National Kidney Foundation. May 4, 2023.
  11. Diabetic Nephropathy. MSD Manual: Professional Version. July 2025.
  12. FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults With Chronic Kidney Disease Associated With Type 2 Diabetes. U.S. Food and Drug Administration. July 9, 2021.
  13. Finerenone (Kerendia). Canadian Agency for Drugs and Technologies in Health. March 2023.
  14. Medicines to Manage Kidney Disease. American Kidney Fund.
  15. Statins. National Kidney Foundation. January 3, 2025.
  16. Living With Chronic Kidney Disease. Centers for Disease Control and Prevention. May 15, 2024.
  17. Kawanami D et al. Significance of Metformin Use in Diabetic Kidney Disease. International Journal of Molecular Sciences. June 14, 2020.
Sandy-Bassin-bio

Sandy Bassin, MD

Medical Reviewer

Sandy Bassin, MD, is an endocrinology fellow at Mount Sinai in New York City. She is passionate about incorporating lifestyle medicine and plant-based nutrition into endocrinology, particularly for diabetes and obesity management.

She trained at the Geisel School of Medicine at Dartmouth, where she taught culinary medicine classes to patients and medical trainees. She continued her training at the Robert Wood Johnson Medical School.

Dr. Bassin has published reviews of nutrition education in medical training and physical activity in type 2 diabetes in Nutrition Reviews, Endocrine Practice, and the American Journal of Lifestyle Medicine. She has been featured on the Physician to Physician Plant-Based Nutrition podcast and given many presentations on lifestyle interventions in endocrine disorders.

She stays active through yoga and gardening, and loves to cook and be outdoors.

Adam Felman

Author
Adam is a freelance writer and editor based in Sussex, England. He loves creating content that helps people and animals feel better. His credits include Medical News Today, Greatist, ZOE, MyLifeforce, and Rover, and he also spent a stint as senior updates editor for Screen Rant.

As a hearing aid user and hearing loss advocate, Adam greatly values content that illuminates invisible disabilities. (He's also a music producer and loves the opportunity to explore the junction at which hearing loss and music collide head-on.)

In his spare time, Adam enjoys running along Worthing seafront, hanging out with his rescue dog, Maggie, and performing loop artistry for disgruntled-looking rooms of 10 people or less.